Lung cancer drug levels under the microscope
NCT ID NCT04557007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study looked at how much of the immunotherapy drug pembrolizumab stays in the blood of patients with advanced non-small cell lung cancer. Researchers measured drug levels and immune responses in 80 patients receiving pembrolizumab alone or with chemotherapy. The goal was to see if drug concentration relates to how well the cancer responds or to side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab
What this could lead to
If successful, this study could help doctors personalize pembrolizumab dosing for lung cancer patients, potentially improving outcomes and reducing side effects.
What could go wrong
This is an observational study, not a treatment trial. It was terminated early, so results may be limited and not conclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St Olavs University Hospital
Trondheim, Norway